Abstract
Introduction

61
Parkinson's disease (PD) is the second most common neurogenerative disease in the world. Its 
89
More recently, there is growing recognition that PD is a systemic disease, involving both .
96
In addition to this pleomorphic distribution of Lewy bodies, the disease is understood as 97 heterogeneous, with motor symptoms (such as resting tremor, cogwheel rigidity, bradykinesia,
98
and postural instability) and multiple non-motor symptoms. These less-recognized non-motor symptoms still receive less therapeutic attention, although they might have an even more 100 pronounced impact on quality of life than the classic cardinal signs [10] [11] [12] .
102
Cohort studies have found that non-motor symptoms do not homogenously involve all patients 103 and have identified subgroups of patients with distinct patterns of disease progression and 104 severity of these symptoms. This heterogeneity in the timeline of alpha-synuclein emergence in 105 the CNS and in the severity of non-motor symptoms led a group of researchers to propose the 106 existence of "non-motor subtypes" of Parkinson's disease 13, 14 . According to this hypothesis 13 , there 107 would be at least three distinct phenotypes: (1) brain stem, with late-onset hyposmia, and the which the pathology spreads more rapidly to the cerebral cortex and nuclei of the basal forebrain, 121 associated with more diffuse cholinergic, noradrenergic and dopaminergic denervation 13, 18, 19 .
123
Longitudinal observational studies that seek to identify the mechanism of cognitive 124 neurodegeneration in PD have non-uniformly clustered patients, and the considerable variability 125 in the specific operational definitions of mild cognitive impairment (MCI) is a problem yet to be 126 solved, which limits comparability between studies and, consequently, its predictive capacity.
128
Understanding the progression of brain damage in PD dementia has advanced through studies Correlations between domain-specific cognitive dysfunctions and regional cerebral volumetric ongoing search for a magnetic resonance biomarker that is both feasible and reliable.
170
In a cohort of incident cases of PD (early stage), using DTI images processed through Tract- 
General Objectives
197
The study aims to: It is a prospective analytical observational study (concurrent cohort) with a simultaneous case- Parkinson's disease patients that fulfill the following criteria will be invited to participate in the Participants of the control group must (a) ability to understand written Portuguese (illiteracy) ;
286
(b) will to return for reassessment (c) paired age and schooling with the disease patients group.
288
Exclusion criteria
290
We will exclude recruitment candidates who present with: (a) dementia at the time of 365 366 In the statistical analysis, the effect of variables will be considered through moderation and 367 mediation analysis; a possible bias related to distinct Hoehn and Yahr stages or disease subtypes 368 at the time of recruitment for the study will be managed by cluster analysis of non-motor data. that determines that a borderline score is between z score of -1.3 and -2.0, and an extremely low 380 score below -2.0, will also be used.
Confounding and modifying variables
382
According to the criteria of the American Psychiatric Association, 2013 59 , mild neurocognitive 383 impairment will be diagnosed when there is a cognitive test in the range of 1 to 2 SD below the 384 normative data, or between the 3rd and 16th percentiles.
386
The three criteria will have their diagnostic yield compared during the study. Demographic, clinical data (disease duration, age of onset, the equivalent daily dose of levodopa,
398
comorbidities, medications in use, family history) and neuropsychological data will be collected,
399
with pre-specified quantitative measures being performed, with planned follow-up evaluations 400 (Figure 1 ).
402
The following instruments will be used: (QUIP-RS) 80 .
445
Accompanying intervals
446 447
Participants will be evaluated longitudinally 3 times, on T0, T18 months and T48 months,
448
following the detailed protocol mentioned above, and detailed in Figure 1 . 
13
The participants will be examined in a brief neuroimaging protocol in a high field magnetic 453 resonance imaging device, where specific imaging sequences will be acquired for the ordinal sequence according to its nature.
516
The MRI data will be analyzed by generalized linear models (GLM), with pipeline entry in
517
FreeSurfer software. As a method of controlling differences (confounding variables, subgroups,
518
and interactions) between groups, we intend to use a clustering strategy.
520
It is planned to collect the data in an electronic format, with a mechanism that blocks the loading 521 of information if there are missing or unaccounted items, as a way to avoid "missing data".
522
Imputation of missing data will be performed by 'mice' R package. Missing will be treated as
523
MAR (missing at random). will be tested and compared to detect that algorithm that best predicts (through its specific 543 features) the studied outcome. It will use the caret R package, which integrates hundreds of other 544 packages. The Deep Learning Toolbox, from Matlab, will also be explored, to determine the 545 artificial inteligence algorithm with the best predictive performance. clinical trials for treatment and prevention of cognitive decline.
556
Evaluation by the research ethics committee 557 558
The study will respect the declaration of Helsinki's ethical principles for medical research 559 involving human subjects. Its protocol was submitted for analysis by the Brasilia University Ministry of Health. All the participants will receive complete information about the study and the 564 data collection will only start after the signature of the consent form.
566
Risks and benefits assessment 567 568 No risk is foreseen for the participants of the research, since the study has a purely observational The study will be submitted to the analysis of funding available from support and research 
